SENL101 Autologous T Cell Injection in Adults With Relapsed or Refractory CD7+ Hematolymphoid Malignancies
NCT05398614
·
clinicaltrials.gov ↗
PHASE1
Phase
UNKNOWN
Status
18
Enrollment
INDUSTRY
Sponsor class
Conditions
T-ALL
Lymphoma, T-Cell
Interventions
BIOLOGICAL:
SENL101
Sponsor
Hebei Senlang Biotechnology Inc., Ltd.